PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 13, 20260 citations

Neuroprotective Effects of Esketamine in Central Nervous System Disorders: Mechanisms and Cellular Targets.

View Full Paper
CZChendi ZhaoYWYang WangJWJinglang Wu

Key Points

  • This review aims to summarize the neuroprotective effects of esketamine in central nervous system disorders and explore its underlying mechanisms.
  • Reviewed existing literature on esketamine's effects in CNS disorders
  • Analyzed cellular processes affected by esketamine, including apoptosis, inflammation, and glial functions
  • Discussed molecular pathways involved in esketamine's action
  • Esketamine shows neuroprotective properties through anti-inflammatory, antiapoptotic, and antioxidant effects.
  • It influences neuronal apoptosis, microglial polarization, and astrocytic functions.
  • Molecular mechanisms primarily involve inflammatory pathways and signaling cascades relevant to neurological disorders.

Abstract

Esketamine (ESK), the dextrorotatory enantiomer of ketamine, is an antagonist of the N-methyl-D-aspartic acid (NMDA) receptor. ESK is considered an effective anesthetic because of its ability to mitigate postoperative pain and opioid use. Recently, it has attracted significant research attention for its fast-acting antidepressant effects. Given the advantages of ESK in both perioperative and postoperative contexts, foundational research into this molecule is progressively moving forward. Accumulating evidence suggests that ESK possesses anti-inflammatory, antiapoptotic and antioxidant characteristics in various diseases. This review summarizes the neuroprotective effects of ESK in central nervous system (CNS) disorders. ESK-mediated cellular processes, including neuronal apoptosis, microglial polarization and astrocytic functions, are also summarized. In addition, the underlying molecular mechanisms of ESK are discussed, with a focus on inflammatory pathways and signalling cascades in neurological disorders.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhao et al. (2026) studied this question.

synapsesocial.com/papers/69b3ac8102a1e69014cce4d9https://doi.org/10.1111/bcpt.70221
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A comprehensive review of the clinical progress of esketamine: From anesthesia to antidepressant therapy2026 · 1 citations
  2. 2Progress in the Application of Esketamine During the Perioperative Period2026 · 2 citations
  3. 3Clinical Benefits and Challenges of Esketamine in Elderly Patients During the Perioperative Period2025 · 6 citations
  4. 4The Dopaminergic Effects of Esketamine are Mediated by a Dual Mechanism Involving Glutamate and Opioid Receptors2024 · 1 citations
  5. 5Research Progress of Esketamine in Painless Endoscopy2024